<p><strong><span style="text-decoration: underline;">Release Date</span></strong> <br />
  February  4th, 2015<br />
<br />
<strong><span style="text-decoration: underline;">Expiration Date</span></strong> <br />
February  4th, 2016<br />
<strong><span style="text-decoration: underline;"><br />
Faculty<br />
</span>Christopher Lieu, MD</strong><br>
University of Colorado<br>
Aurora, Colorado, United States</p>
<p><strong>Edith Mitchell, MD, FACP</strong><br>
  Thomas Jefferson University <br>
Philadelphia, Pennsylvania, United States</p>
<p><strong><span style="text-decoration: underline;">Learning Objectives</span></strong><br />
After completion of this educational  activity, participants should be able to:</p>
<ul class="bullets">
  <li>Evaluate emerging       clinical trial data in metastatic colorectal cancer (mCRC), including       studies focused on the safety and efficacy of novel targeted therapies</li>
  <li>Identify strategies       to individualize treatment selection and sequencing for patients with mCRC       based on mutation testing, extent of metastatic disease, and other patient       and disease characteristics</li>
  <li>Describe best       practices for monitoring and managing treatment-associated adverse events       in patients with mCRC to improve patient care</li>
</ul>
<p><strong><span style="text-decoration: underline;"><br />
Provider </span></strong><br />
This activity is provided by prIME Oncology. <br />
<strong><span style="text-decoration: underline;"><br />
Support </span></strong><br />
This educational activity is supported by grant from Regeneron Pharmaceuticals and Sanofi.<br />
<strong><span style="text-decoration: underline;"><br />
Target Audience </span></strong><br />
This educational activity is specifically designed for medical oncologists, surgical and radiation oncologists, and other healthcare professionals interested and/or involved in the treatment of patients with colorectal cancer (CRC).</p>
<p><strong><span style="text-decoration: underline;">  Continuing  Education</span></strong><br />
prIME Oncology is accredited by the Accreditation Council for  Continuing Medical Education (ACCME<sup>&reg;</sup>) to provide continuing medical education  for physicians.</p>
<p><img width="93" height="55" alt="ACCME" src="~/media/Images/Sponsor/accme.ashx" /></p>
<p>prIME Oncology designates this enduring activity for a maximum of X<em> AMA  PRA Category 1 Credits&trade;.&nbsp;</em>
<br />
<br />
<strong><span style="text-decoration: underline;">Method of Participation</span></strong><br />
There  are no fees for participating in and receiving CME credit for this activity. In  order to receive credit, participants must successfully complete the online  posttest and activity evaluation. Your participation in this CME activity will  be recorded in prIME Oncology's database. However, upon request, your CME  credit certificate will be emailed to you. <br>
<br>
Technical requirements may be found  under the <a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms of  Use.</a><br />
<br />
Links to the posttest are available on the video player pages.<br />
<br />
In order to receive credit, participants must successfully complete the  online posttest with XX%  or higher.</p>
<p><strong><span style="text-decoration: underline;">Disclosure of Relevant Financial Relationships</span></strong><br />
  prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Lieu has disclosed that he has received consulting fees from Sanofi-Aventis. He has agreed to represent that the information provided is complete and truthful. 

Dr Mitchell has disclosed that she has received consulting fees from Genentech Advisory Board and contracted research funding (to the university) from Lilly and Genentech. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed: 
•	Amy Furedy, RN, OCN (clinical content reviewer/planner) - no relevant financial relationships
•	Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
•	Christi Gray (editorial content reviewer) – no relevant financial relationships
<br />
  <br />
  <strong><span style="text-decoration: underline;">Faculty Disclosures</span></strong><br />
  The faculty reported the following financial relationships or relationships to  products or devices they or their spouses/life partners have with commercial  interests related to the content of this CME activity:<br />
  <br />
  Dr le Coutre has disclosed he received consultation fees from Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. He also has performed contracted research for Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
  <br />
  <br />
  Dr Lipton has disclosed that he has received consulting fees from and has performed contracted research for Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
  <br />
  <br />
  <strong>The employees of prIME Oncology have disclosed:</strong></p>
<ul class="bullets">
  <li>Briana Betz, PhD (clinical content reviewer/planner) - no relevant financial relationships</li>
    <li>Trudy Stoddert, ELS (editorial content reviewer) - no relevant financial relationships</li>
</ul>
<br />
<p><strong><span style="text-decoration: underline;">
Disclosure Regarding Unlabeled Use</span></strong><br />
This activity may contain discussion of published and/or investigational uses  of agents that are not indicated by the US Food and Drug Administration or  European Medicines Agency. Please refer to the official prescribing information  for each product discussed for discussions of approved indications, contraindications,  and warnings.<strong><span style="text-decoration: underline;"><br />
</span></strong><br />
<strong><span style="text-decoration: underline;">Disclaimer</span></strong><br />
Participants have an implied responsibility to use the newly acquired  information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline  for patient management. Any procedures, medications, or other courses of  diagnosis or treatment discussed or suggested in this activity should not be  used by clinicians without evaluation of their patients' conditions and  possible contraindications or dangers in use, review of any applicable  manufacturer's product information, and comparison with recommendations of  other authorities.</p>
